297 related articles for article (PubMed ID: 33515349)
1. Cytotoxic effect of 6-Shogaol in Imatinib sensitive and resistant K562 cells.
Ozkan T; Hekmatshoar Y; Pamuk H; Ozcan M; Yaman G; Yagiz GC; Akdemir C; Sunguroglu A
Mol Biol Rep; 2021 Feb; 48(2):1625-1631. PubMed ID: 33515349
[TBL] [Abstract][Full Text] [Related]
2. Assessment of azithromycin as an anticancer agent for treatment of imatinib sensitive and resistant CML cells.
Ozkan T; Hekmatshoar Y; Karabay AZ; Koc A; Altinok Gunes B; Karadag Gurel A; Sunguroglu A
Leuk Res; 2021 Mar; 102():106523. PubMed ID: 33607534
[TBL] [Abstract][Full Text] [Related]
3. Characterization of imatinib-resistant K562 cell line displaying resistance mechanisms.
Hekmatshoar Y; Ozkan T; Altinok Gunes B; Bozkurt S; Karadag A; Karabay AZ; Sunguroglu A
Cell Mol Biol (Noisy-le-grand); 2018 May; 64(6):23-30. PubMed ID: 29808796
[TBL] [Abstract][Full Text] [Related]
4. Some 2-[4-(1H-benzimidazol-1-yl) phenyl]-1H-benzimidazole derivatives overcome imatinib resistance by induction of apoptosis and reduction of P-glycoprotein activity.
Hekmatshoar Y; Ozkan T; Alp M; Gurkan-Alp AS; Sunguroglu A
Chem Biol Drug Des; 2023 Dec; 102(6):1521-1533. PubMed ID: 37722976
[TBL] [Abstract][Full Text] [Related]
5. A novel tubulin polymerization inhibitor, MPT0B206, downregulates Bcr-Abl expression and induces apoptosis in imatinib-sensitive and imatinib-resistant CML cells.
Chen CW; Lee YL; Liou JP; Liu YH; Liu CW; Chen TY; Huang HM
Apoptosis; 2016 Sep; 21(9):1008-18. PubMed ID: 27344662
[TBL] [Abstract][Full Text] [Related]
6. Secretion of IL-1β from imatinib-resistant chronic myeloid leukemia cells contributes to BCR-ABL mutation-independent imatinib resistance.
Lee CR; Kang JA; Kim HE; Choi Y; Yang T; Park SG
FEBS Lett; 2016 Feb; 590(3):358-68. PubMed ID: 26831735
[TBL] [Abstract][Full Text] [Related]
7. Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia.
Bandyopadhyay S; Li J; Traer E; Tyner JW; Zhou A; Oh ST; Cheng JX
PLoS One; 2017; 12(7):e0179558. PubMed ID: 28719608
[TBL] [Abstract][Full Text] [Related]
8. A molecular and biophysical comparison of macromolecular changes in imatinib-sensitive and imatinib-resistant K562 cells exposed to ponatinib.
Yandim MK; Ceylan C; Elmas E; Baran Y
Tumour Biol; 2016 Feb; 37(2):2365-78. PubMed ID: 26373734
[TBL] [Abstract][Full Text] [Related]
9. Arsenic induces apoptosis of multidrug-resistant human myeloid leukemia cells that express Bcr-Abl or overexpress MDR, MRP, Bcl-2, or Bcl-x(L).
Perkins C; Kim CN; Fang G; Bhalla KN
Blood; 2000 Feb; 95(3):1014-22. PubMed ID: 10648417
[TBL] [Abstract][Full Text] [Related]
10. Overexpression of
Deng Y; Li X; Feng J; Zhang X
Biosci Rep; 2018 Jun; 38(3):. PubMed ID: 29559564
[TBL] [Abstract][Full Text] [Related]
11. Phenotypic and functional characterization of subpopulation of Imatinib resistant chronic myeloid leukemia cell line.
Hekmatshoar Y; Karadag Gurel A; Ozkan T; Rahbar Saadat Y; Koc A; Karabay AZ; Bozkurt S; Sunguroglu A
Adv Med Sci; 2023 Sep; 68(2):238-248. PubMed ID: 37421850
[TBL] [Abstract][Full Text] [Related]
12. Ketoconazole Reverses Imatinib Resistance in Human Chronic Myelogenous Leukemia K562 Cells.
Prado-Carrillo O; Arenas-Ramírez A; Llaguno-Munive M; Jurado R; Pérez-Rojas J; Cervera-Ceballos E; Garcia-Lopez P
Int J Mol Sci; 2022 Jul; 23(14):. PubMed ID: 35887063
[TBL] [Abstract][Full Text] [Related]
13. [Growth inhibition and differentiation of imatinib-resistant chronic myeloid leukemia cell induced by cell differentiation agent in vitro].
Wang XD; Qiu L; Lu RZ; Chen LJ; Zhan ZM; Han BH; Zhang BL; Ma J
Zhonghua Yi Xue Za Zhi; 2007 Dec; 87(48):3399-405. PubMed ID: 18476538
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a highly potent kinase inhibitor capable of overcoming multiple imatinib-resistant ABL mutants for chronic myeloid leukemia (CML).
Lu T; Cao J; Zou F; Li X; Wang A; Wang W; Liang H; Liu Q; Hu C; Chen C; Hu Z; Wang W; Li L; Ge J; Shen Y; Ren T; Liu J; Xia R; Liu Q
Eur J Pharmacol; 2021 Apr; 897():173944. PubMed ID: 33581133
[TBL] [Abstract][Full Text] [Related]
15. Targeting Hedgehog signaling pathway and autophagy overcomes drug resistance of BCR-ABL-positive chronic myeloid leukemia.
Zeng X; Zhao H; Li Y; Fan J; Sun Y; Wang S; Wang Z; Song P; Ju D
Autophagy; 2015; 11(2):355-72. PubMed ID: 25701353
[TBL] [Abstract][Full Text] [Related]
16. The chimeric ubiquitin ligase SH2-U-box inhibits the growth of imatinib-sensitive and resistant CML by targeting the native and T315I-mutant BCR-ABL.
Ru Y; Wang Q; Liu X; Zhang M; Zhong D; Ye M; Li Y; Han H; Yao L; Li X
Sci Rep; 2016 Jun; 6():28352. PubMed ID: 27329306
[TBL] [Abstract][Full Text] [Related]
17. Persistent STAT5-mediated ROS production and involvement of aberrant p53 apoptotic signaling in the resistance of chronic myeloid leukemia to imatinib.
Cheng Y; Hao Y; Zhang A; Hu C; Jiang X; Wu Q; Xu X
Int J Mol Med; 2018 Jan; 41(1):455-463. PubMed ID: 29115375
[TBL] [Abstract][Full Text] [Related]
18. Cryptotanshinone acts synergistically with imatinib to induce apoptosis of human chronic myeloid leukemia cells.
Ge Y; Yang B; Xu X; Dai Q; Chen Z; Cheng R
Leuk Lymphoma; 2015 Mar; 56(3):730-8. PubMed ID: 24884318
[TBL] [Abstract][Full Text] [Related]
19. Induction of heme oxygenase-1 by Na+-H+ exchanger 1 protein plays a crucial role in imatinib-resistant chronic myeloid leukemia cells.
Ma D; Fang Q; Wang P; Gao R; Wu W; Lu T; Cao L; Hu X; Wang J
J Biol Chem; 2015 May; 290(20):12558-71. PubMed ID: 25802333
[TBL] [Abstract][Full Text] [Related]
20. MPT0B169, a New Antitubulin Agent, Inhibits Bcr-Abl Expression and Induces Mitochondrion-Mediated Apoptosis in Nonresistant and Imatinib-Resistant Chronic Myeloid Leukemia Cells.
Wong SM; Liu FH; Lee YL; Huang HM
PLoS One; 2016; 11(1):e0148093. PubMed ID: 26815740
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]